TickerFacts.

Myriad Genetics Inc (MYGN): Long-Term Debt

Annual figures by period end, from SEC filings.

$119.90M
As of 2025-12-31
$120.70M
As of 2026-06-30
-11.8%
5-year compound annual growth
$233.50M2017-06-30: $99.10M2018-06-30: $9.30M2019-06-30: $233.50M2020-06-30: $224.40M2020-12-31: $224.80M2021-12-31: $02022-12-31: $02025-12-31: $119.90M$119.90M
2017-06-30 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$119.90Mn/a2026-02-24, Balance as of period end
No annual figure between 2022-12-31 and 2025-12-31.
2022-12-31$0n/a2023-03-01, Balance as of period end
2021-12-31$0-100.0%2022-02-25, Balance as of period end
2020-12-31$224.80Mn/a2022-02-25, Balance as of period end
2020-06-30$224.40M-3.9%2020-08-13, Balance as of period end
2019-06-30$233.50Mn/m2020-08-13, Balance as of period end
2018-06-30$9.30M-90.6%2019-08-13, Balance as of period end
2017-06-30$99.10Mn/a2018-08-24, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Myriad Genetics Inc (MYGN)2025-12-31$119.90Mn/a
QuidelOrtho Corp (QDEL)2025-12-28$2.70B+8.4%
Idexx Laboratories Inc (IDXX)2025-12-31$450.00M-27.2%
Alpha Teknova, Inc. (TKNO)2025-12-31$13.12M+39.0%
Immucell Corp (ICCC)2025-12-31$9.10Mn/a
Aspira Women's Health Inc. (AWHL)2025-12-31$1.28M-15.3%
Volitionrx Ltd (VNRX)2025-12-31$6.71M+39.4%

Compare MYGN, QDEL, IDXX, TKNO side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗